Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Immunol. 2003 Feb;24(2):58-61.

Determinant spreading and tumor responses after peptide-based cancer immunotherapy.

Author information

1
Department of Medicine, 54-140 CHS, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA. aribas@mednet.ucla.edu

Abstract

Modern immunological assays are very sensitive for detection of antigen-specific T cells. These assays are used to detect increased levels of T cells after peptide-based immunotherapy for cancer in an attempt to describe surrogate endpoints correlated with anti-tumor activity. Recent reports demonstrate that determinant spreading develops in a high frequency of subjects with tumor regression responses after this type of immunotherapy and could be valuable for trial monitoring and the design of more effective vaccines.

PMID:
12547500
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center